EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC 4.0

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

Alessandro De Carlo iD, Elena Maria Tosca iD, Mirjam Crul iD, Tim Schutte iD, Lia van Zuijlen, Idris Bahce, Medhat M Said iD, Jan Buter, Harmen Huls, Paolo Magni iD, Imke Bartelink iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70413 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Alessandro De Carlo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology (BMS Lab), Department of Electrical Computer and Biomedical Engineering, U…. Hauptthemen laut MEDLINE: Carboplatin, Models, Biological, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization.

Methods

Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model development, focusing on lung, gynaecological and gastric/oesophageal cancers. Platelet (PLT) and neutrophil (NT) counts, along with patient‐specific covariates (e.g., age, serum albumin, eGFR), were extracted from Electronic Health Records and used in the analysis. Given the absence of pharmacokinetic (PK) samples, PK parameters were derived from a literature carboplatin pop‐PK model. Model applicability to inform personalized carboplatin dosing was evaluated on a separate cohort of 210 patients treated between 2022 and 2024 in the same centre.

Results

Two joint Friberg models effectively described carboplatin‐induced myelosuppression. Serum albumin, eGFR and paclitaxel and pemetrexed co‐medications were included in the final model. On the test cohort, >85% of NT and >87% of PLT observations fell within the 90% confidence interval of Bayesian model predictions, confirming that the model can support dose adjustments for subsequent treatment cycles. An example of model‐based dose adjustments is also presented with a simulation study.

Conclusions

The pop‐PK‐PD model demonstrated strong performance in describing and predicting carboplatin‐induced myelosuppression, thus providing a valuable strategy for dose personalization. Further refinements and validation steps are needed before integrating such an approach into clinical workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarboplatinModels, BiologicalAntineoplastic AgentsNeoplasmsHumansFemaleElectronic Health RecordsMaleMiddle AgedAgedPrecision MedicinePaclitaxelBayes TheoremDose-Response Relationship, DrugAdultPemetrexedSerum AlbuminAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsErbB Receptors

Stichwörter der Autor:innen

Bayesian inferencePK‐PD modelingcarboplatin‐dosingcarboplatin‐induced myelosuppressionmodel‐informed precision dosingreal‐world datatoxicity‐based dosing

Substanzen

CarboplatinAntineoplastic AgentsPaclitaxelPemetrexedSerum AlbuminEGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology (BMS Lab), Department of Electrical Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.
  • Department of Clinical Pharmacy & Pharmacology, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
  • Netherlands Cancer Institute, Amsterdam, the Netherlands.

ORCID-Profile: Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Medhat M Said, Paolo Magni, Imke Bartelink

Zitieren

APA

De Carlo, A., Tosca, E. M., Crul, M., Schutte, T., van Zuijlen, L., Bahce, I., Said, M. M., Buter, J., Huls, H., Magni, P., & Bartelink, I. (2026). Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70413

Vancouver

De Carlo A, Tosca EM, Crul M, Schutte T, van Zuijlen L, Bahce I, et al. Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70413

BibTeX
@article{DeCarlo2026,
  author = {De Carlo, Alessandro and Tosca, Elena Maria and Crul, Mirjam and Schutte, Tim and van Zuijlen, Lia and Bahce, Idris and Said, Medhat M and Buter, Jan and Huls, Harmen and Magni, Paolo and Bartelink, Imke},
  title = {Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70413}
}
Kostenlos starten →